Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series

Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M., Guidelines for the pharmacotherapy of schizophrenia in adults, Can J Psychiatry, 62, 9, pp. 604-616, (2017)

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, Et al., Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology, Am J Psychiatry, 174, 3, pp. 216-229, (2017)

Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Et al., The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research, NPJ Schizophr, 6, (2020)

Siskind D, Siskind V, Kisely S., Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis, Can J Psychiatry, 62, 11, pp. 772-777, (2017)

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Et al., The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, Am J Psychiatry, 177, 9, pp. 868-872, (2020)

Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Et al., Clozapine combination and augmentation strategies in patients with schizophrenia-recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group, Schizophr Bull, 46, 6, pp. 1459-1470, (2020)

Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G., Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial, Pharmacopsychiatry, 41, 1, pp. 24-28, (2008)

Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Et al., Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial, Ther Adv Psychopharmacol, 8, 7, pp. 185-197, (2018)

Genc Y, Taner E, Candansayar S., Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study, Adv Ther, 24, 1, pp. 1-13, (2007)

Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B., Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity, J Pharmacol Exp Ther, 280, 1, pp. 73-82, (1997)

Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M., Guidelines for the pharmacotherapy of schizophrenia in adults, Can J Psychiatry, 62, 9, pp. 604-616, (2017)

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, Et al., Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology, Am J Psychiatry, 174, 3, pp. 216-229, (2017)

Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Et al., The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research, NPJ Schizophr, 6, (2020)

Siskind D, Siskind V, Kisely S., Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis, Can J Psychiatry, 62, 11, pp. 772-777, (2017)

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Et al., The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, Am J Psychiatry, 177, 9, pp. 868-872, (2020)

Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Et al., Clozapine combination and augmentation strategies in patients with schizophrenia-recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group, Schizophr Bull, 46, 6, pp. 1459-1470, (2020)

Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G., Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial, Pharmacopsychiatry, 41, 1, pp. 24-28, (2008)

Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Et al., Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial, Ther Adv Psychopharmacol, 8, 7, pp. 185-197, (2018)

Genc Y, Taner E, Candansayar S., Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study, Adv Ther, 24, 1, pp. 1-13, (2007)

Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B., Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity, J Pharmacol Exp Ther, 280, 1, pp. 73-82, (1997)